about
Cell wall assembly in Saccharomyces cerevisiaeEscape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofunginCombination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole.Comparison of echinocandin antifungalsSuppression of sensitivity to drugs and antibiotics by high external cation concentrations in fission yeastNetwork Modeling Reveals Cross Talk of MAP Kinases during Adaptation to Caspofungin Stress in Aspergillus fumigatusEpidemiology of invasive candidiasis: a persistent public health problemCaspofungin: a potential cause of reversible severe thrombocytopenia.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerSynergistic activity of the tyrocidines, antimicrobial cyclodecapeptides from Bacillus aneurinolyticus, with amphotericin B and caspofungin against Candida albicans biofilms.Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicansA novel connection between the Cell Wall Integrity and the PKA pathways regulates cell wall stress response in yeast.Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometryStructure-activity relationship study of the plant-derived decapeptide OSIP108 inhibiting Candida albicans biofilm formation.DL-2-hydroxyisocaproic acid attenuates inflammatory responses in a murine Candida albicans biofilm model.Antifungal agents for the treatment of systemic fungal infections in children.Pneumocystis jirovecii dihydropteroate synthase gene mutations in a group of HIV-negative immunocompromised patients with Pneumocystis pneumonia.Practice guidelines for the diagnosis and management of skin and soft-tissue infections.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phaseEmergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.Penetration of topically administered 0.5-percent caspofungin eye drops into human aqueous humorThe synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent mannerZygomycosis in Immunocompromised non-Haematological Patients.Human pharmacogenomic variations and their implications for antifungal efficacy.A novel antifungal is active against Candida albicans biofilms and inhibits mutagenic acetaldehyde production in vitro.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Novel strategies to fight Candida species infection.Antifungal properties of peptidomimetics with an arginine-[β-(2,5,7-tri-tert-butylindol-3-yl)alanine]-arginine motif against Saccharomyces cerevisiae and Zygosaccharomyces bailii.Systemic antifungal therapy: new options, new challenges.Candida albicans infections in renal transplant recipients: effect of caspofungin on polymorphonuclear cellsTreatment principles for Candida and Cryptococcus.Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.Genomic profiling of fungal cell wall-interfering compounds: identification of a common gene signature.Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.Recent advances in antifungal pharmacotherapy for invasive fungal infections.Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.Combination treatment of invasive fungal infections.
P2860
Q24549234-B2FEE4A3-5455-4CB3-AC28-D1BC6DADBB1EQ24674839-D9079E98-0653-44B7-B61C-F5F8D911978CQ25256122-A1633273-EBCF-420E-92B6-2CF6429BC676Q28273738-4B68588A-9DEF-4FE9-9FE6-7C86A712A323Q28544788-FB2C7092-E34E-4B3F-90DC-0AC93B58E5D0Q28547827-9AC5FC49-8290-4BCF-A84C-DCC234AEE9ACQ29616758-91E90955-17DF-4045-9E99-C73EA6EEEC4AQ33364370-3892FB33-C973-4724-B03E-61F474DB2836Q33650105-D29CC0AB-66D6-4E81-A174-AC8E7DFE8C06Q33798459-262BC7A5-610E-4FED-9DE0-E9C832516421Q33836717-60BC7610-C1D3-4D40-9A76-E6367629DF1DQ33915842-A7DDA912-900C-4122-9EB8-68162614E087Q33938068-7B1B61E6-2520-42A8-9B7C-D167F29F5BF4Q34042198-B6C4EF6D-EEB5-4E54-ADA6-FDD3A0ACBDFEQ34058071-328D9CC3-98F8-4D05-9AC8-D485CA66616BQ34260729-100C746B-C69C-4BB6-9542-371770AFE613Q34437094-5006789B-F924-4713-8755-28EA2E9FA86FQ34445099-A958D5AD-FB4F-40CF-B8DE-C0D5DF382310Q34460523-6E1A307C-E329-490B-A19C-9A3B33557030Q34505582-BED80BDF-5785-4406-9839-E2C565733B06Q34643153-64C8B2AE-4DE8-4DB1-B148-3E501277900BQ34721774-00DBF08F-FAD6-40B2-B129-1B512D8802F4Q34737498-5F9480BF-3F99-4C34-B41A-7A71875AC21AQ34854161-C5527E36-5AB5-41B5-A0A3-9D6ADF3CB1BBQ35010681-8F5C14B2-F177-4420-BB7A-5C03A8517EEDQ35070838-681A61DF-4BBA-4635-9FE3-E81B2CF4A80EQ35175064-160E7166-6DD9-456D-B768-690F6CE298FCQ35185757-45FDD3DA-2DFE-45D3-9F16-53DAB6F66168Q35406737-7D774466-A124-41F8-86D6-DDFC6ABF6524Q35575367-D438E934-7DDE-4C74-80E5-E4FDC71B6665Q35585219-1A63EC91-6997-4470-923B-C645F525AD77Q35598563-22F55CF1-B6B4-4A48-B592-C3C0934014EDQ35664186-49C699F2-E7FE-4FC3-97BD-FE9314077061Q35718542-91F0C739-BA74-4FFD-A485-ADF53339DF29Q35765017-484C5072-116B-4C22-8510-5CCEFDD09BA5Q35833407-67402750-31CD-4F3B-B9F2-45AE98975ECBQ35917383-81EAAABC-B514-4F64-8285-A89675974432Q35959489-792BDFF1-68C8-4E9D-9EE2-8BEB017E8F65Q35966128-6A3F93DC-5E8E-474B-BAC6-13E0C898304DQ36011378-2DE4380A-159F-4337-A619-DB0313965F83
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Caspofungin.
@ast
Caspofungin.
@en
Caspofungin.
@nl
type
label
Caspofungin.
@ast
Caspofungin.
@en
Caspofungin.
@nl
prefLabel
Caspofungin.
@ast
Caspofungin.
@en
Caspofungin.
@nl
P356
P1476
Caspofungin.
@en
P2093
David A Stevens
Stanley C Deresinski
P304
P356
10.1086/375080
P407
P577
2003-05-19T00:00:00Z